Full video transcriptClick to expand
Auto-generated transcript of @stanmilsom1's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So something else I've been meaning to try for a long time is Cilank and Cimaps.
- 0:05Obviously some maps I'm going to be taking first thing in the morning for alertness to wake me
- 0:09up for the day and get me ready for busy days ahead. Good for like mental clarity and things
- 0:14like that. And then Cilank I'm going to take the evening to wind down after a busy day,
- 0:18sort of calm me down, de-stress me and things like that. So yeah I've been looking forward to
- 0:22these ones and I will post an update in a few days time.
Selank and semax nasal sprays: what the science actually says
Quick answer
Semax and selank are synthetic neuropeptides developed in Russia with limited peer-reviewed human trial data, primarily studied in clinical populations such as stroke and anxiety disorder patients rather than healthy adults. Neither compound is approved by the FDA or EMA, and nasal spray formulations available through research or compounding channels carry variable quality control risks. Stan's proposed morning-stimulant and evening-anxiolytic dosing schedule reflects the general pharmacological profiles described in the literature, but his planned evaluation window of a few days is insufficient to draw meaningful conclusions from subjective experience.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Selank and semax nasal sprays: what the science actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Selank and semax nasal sprays: what the science actually says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Selank and semax nasal sprays: what the science actually says" from Stan milsom. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semax and selank are synthetic neuropeptides developed in Russia with limited peer-reviewed human trial data, primarily studied in clinical populations such as stroke and anxiety disorder patients rather than healthy adults.
The reason this review is not generic is the source wording and the canonical claim label "peptides trying selank and semax nasal sprays selank semax nasalspray." In this clip, the useful excerpt is: "So something else I've been meaning to try for a long time is Cilank and Cimaps." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Functional Connectomic Approach to Studying Selank and Semax Effects (2020), Effects of Semax on the Default Mode Network of the Brain (2018), and Therapeutic Peptides: Applications, Challenges, and Future Directions (2026), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semax and selank are synthetic neuropeptides developed in Russia with limited peer-reviewed human trial data, primarily studied in clinical populations such as stroke and anxiety disorder patients rather than healthy adults.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semax and selank are synthetic neuropeptides developed in Russia with limited peer-reviewed human trial data, primarily studied in clinical populations such as stroke and anxiety disorder patients rather than healthy adults. Neither compound is approved by the FDA or EMA, and nasal spray formulations available through research or compounding channels carry variable quality control risks. Stan's proposed morning-stimulant and evening-anxiolytic dosing schedule reflects the general pharmacological profiles described in the literature, but his planned evaluation window of a few days is insufficient to draw meaningful conclusions from subjective experience.
- Semax is a synthetic ACTH analogue studied primarily in Russia; the bulk of human trial data involves stroke and cognitive impairment patients, not healthy adults seeking morning alertness.
- Selank's anxiolytic properties are documented in at least one Russian controlled trial (Semenova et al., 2010), but sample sizes are small and independent Western replication is lacking.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Semax is a synthetic ACTH analogue studied primarily in Russia; the bulk of human trial data involves stroke and cognitive impairment patients, not healthy adults seeking morning alertness.
- Selank's anxiolytic properties are documented in at least one Russian controlled trial (Semenova et al., 2010), but sample sizes are small and independent Western replication is lacking.
- Neither semax nor selank is FDA or EMA approved for any indication; nasal spray formulations available in the US and UK exist in a regulatory grey zone with real purity and dosing risks.
- The intranasal route does have mechanistic support for peptide brain delivery (Thorne et al., 2004, Neuroscience), which is one reason researchers and self-experimenters favour it over oral dosing.
- Placebo response in nootropic self-experimentation is well-documented and substantial; a few-day personal trial cannot reliably attribute subjective changes to the compound.
- Anyone considering these peptides should consult a physician with peptide pharmacology experience and verify the sourcing and third-party testing of any product before use.
- The morning-stimulant and evening-anxiolytic framing Stan describes is loosely consistent with each peptide's general profile, but treating it as a proven protocol overstates what the evidence currently supports.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @stanmilsom1 actually say?
Stan is trying two Russian-developed peptide nasal sprays and has a clear plan for each: semax in the morning "for alertness" and mental clarity, selank in the evening to "calm me down, de-stress me." That's basically the whole claim. No dosing details, no stacking warnings, just a timing strategy based on each peptide's perceived profile. He promises an update in a few days.
To be fair, this is a low-key video. He's not selling anything or claiming these peptides cured his anxiety or supercharged his cognition. He's framing it as personal experimentation. That matters when evaluating what he actually put out there versus what the comments section might run with.
Does the science back this up?
Partially, and with significant caveats. The stimulating-versus-calming split he describes isn't invented from nowhere, but the human evidence base is thin enough that anyone presenting it as settled science should slow down.
Semax is a synthetic analogue of ACTH(4-7) developed in Russia and has been studied primarily there, which creates real problems for independent replication. Animal studies do show increased dopaminergic and serotonergic activity in rodent models (Dolotov et al., 2006, Neurochemical Research), and some human trials conducted in Russia report cognitive benefits in stroke rehabilitation patients. Whether those effects translate to healthy adults using it as a morning nootropic is a genuine unknown. The "alertness" framing isn't unreasonable, but calling it evidence-based for healthy users would be a stretch.
Selank is a synthetic analogue of tuftsin and has shown anxiolytic properties in animal models without the sedation profile typical of benzodiazepines (Semenova et al., 2010, Bulletin of Experimental Biology and Medicine). Some small Russian trials report reduced anxiety in humans. An "evening wind-down" framing is plausible given the mechanism, but again, these studies are small, often Russian-only, and not replicated in Western peer-reviewed literature.
What did they get wrong (or right)?
He got the directional framing roughly right. Semax does have stimulating properties in the literature; selank does have anxiolytic associations. Credit where it's due.
What he glosses over, though, is that neither peptide is approved by the FDA or the EMA for any indication. These are not regulated medications in the US or UK. The nasal spray formulations circulating in the peptide community are almost entirely sourced from research chemical suppliers or compounding pharmacies operating in regulatory grey zones. Quality control is a real issue, not a theoretical one.
He also says he'll "post an update in a few days." A few days is far too short a window to evaluate either peptide meaningfully. The Russian human studies on selank ran for weeks. Interpreting how you feel after two or three days of nasal spray use and attributing it to the peptide rather than placebo, expectation, or routine changes is scientifically unreliable. That's not a criticism unique to Stan, it's a problem with almost every n=1 peptide video on this platform.
What should you actually know?
If you're curious about semax or selank, the honest answer is that the science is genuinely interesting and genuinely incomplete. These are not proven nootropics for healthy adults. They are not approved drugs. The research that does exist comes largely from a single country's scientific ecosystem, which limits how much confidence anyone should have.
Nasal delivery of peptides does have pharmacological logic behind it. The intranasal route can bypass the blood-brain barrier more effectively than oral administration for certain compounds (Thorne et al., 2004, Neuroscience). That's a real mechanism. It does not, however, mean that every peptide delivered nasally will produce the cognitive effects its proponents claim.
Before trying either compound, anyone seriously considering it should talk to a physician familiar with peptide pharmacology, understand that sourcing and purity verification matter enormously, and be genuinely skeptical of their own subjective experience as evidence of anything. The placebo response in nootropic self-experimentation is not small. It is substantial.
The bottom line
Stan's timing logic is not completely made up, but it is significantly ahead of the human evidence. Semax probably has some stimulating properties; selank probably has some anxiolytic properties. Whether either does what he expects in a healthy person, delivered nasally, at unspecified doses, over a few days, is something no current published study can confidently confirm. Watch his follow-up with appropriate skepticism, including the possibility that he'll feel exactly what he expects to feel.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Stan milsom · TikTok creator
24.0K views on this video
Trying selank and semax nasal sprays #selank #semax #nasalspray #peptide #consistency
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semax?
Semax is a synthetic ACTH analogue studied primarily in Russia; the bulk of human trial data involves stroke and cognitive impairment patients, not healthy adults seeking morning alertness.
What does the video say about selank's anxiolytic properties?
Selank's anxiolytic properties are documented in at least one Russian controlled trial (Semenova et al., 2010), but sample sizes are small and independent Western replication is lacking.
What does the video say about neither semax nor selank?
Neither semax nor selank is FDA or EMA approved for any indication; nasal spray formulations available in the US and UK exist in a regulatory grey zone with real purity and dosing risks.
What does the video say about the intranasal route does have mechanistic support for peptide brain?
The intranasal route does have mechanistic support for peptide brain delivery (Thorne et al., 2004, Neuroscience), which is one reason researchers and self-experimenters favour it over oral dosing.
What does the video say about placebo response in nootropic self-experimentation?
Placebo response in nootropic self-experimentation is well-documented and substantial; a few-day personal trial cannot reliably attribute subjective changes to the compound.
What does the video say about anyone considering these peptides should consult a physician with peptide?
Anyone considering these peptides should consult a physician with peptide pharmacology experience and verify the sourcing and third-party testing of any product before use.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Stan milsom, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.